Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$25.74
+6.1%
$22.11
$12.21
$41.31
$712.48M-0.27645,433 shs895,981 shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$16.30
+2.3%
$14.88
$11.51
$21.50
$2.78B0.5299,408 shs163,098 shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$53.46
+6.3%
$46.99
$35.63
$54.23
$2.49B0.97460,889 shs703,097 shs
Vericel Corporation stock logo
VCEL
Vericel
$41.50
+3.3%
$41.78
$37.39
$63.00
$2.02B1.32418,346 shs413,446 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
+6.14%+7.79%+11.00%+58.50%-0.16%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
+2.32%+3.89%+2.13%+30.09%-3.26%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
+6.35%+8.90%+13.62%+36.66%+46.07%
Vericel Corporation stock logo
VCEL
Vericel
+3.31%+0.10%-5.29%-0.95%-9.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.3026 of 5 stars
3.41.00.00.02.12.50.6
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1.683 of 5 stars
2.04.00.00.01.40.01.9
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3.0887 of 5 stars
2.60.00.04.22.01.70.6
Vericel Corporation stock logo
VCEL
Vericel
2.9479 of 5 stars
3.51.00.00.03.30.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.80
Moderate Buy$42.3864.63% Upside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.00
Hold$19.0016.56% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3.13
Buy$65.5022.52% Upside
Vericel Corporation stock logo
VCEL
Vericel
3.00
Buy$61.1447.33% Upside

Current Analyst Ratings Breakdown

Latest ANAB, HCM, MIRM, and VCEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00
6/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$22.00 ➝ $38.00
5/29/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
5/28/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $90.00
5/22/2025
Vericel Corporation stock logo
VCEL
Vericel
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.00
5/19/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$73.00
5/13/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy
5/13/2025
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/13/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.00
5/9/2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.00
5/6/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$52.00 ➝ $54.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$91.28M8.28N/AN/A$2.33 per share11.05
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.51$0.29 per share55.46$4.43 per share3.68
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$336.89M7.86N/AN/A$4.70 per share11.37
Vericel Corporation stock logo
VCEL
Vericel
$237.22M8.81$0.32 per share128.55$5.92 per share7.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0011.16N/AN/AN/AN/A8/7/2025 (Estimated)
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)
Vericel Corporation stock logo
VCEL
Vericel
$10.36M$0.031,383.7994.32N/A1.25%1.09%0.73%7/30/2025 (Estimated)

Latest ANAB, HCM, MIRM, and VCEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.04N/AN/AN/A$64.61 millionN/A
8/6/2025Q2 2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.31N/AN/AN/A$107.91 millionN/A
8/4/2025Q2 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.47N/AN/AN/A$11.55 millionN/A
5/14/2025Q1 2025
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million
5/8/2025Q1 2025
Vericel Corporation stock logo
VCEL
Vericel
-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million
5/5/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
Vericel Corporation stock logo
VCEL
Vericel
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
8.25
8.25
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.32
3.22
3.04
Vericel Corporation stock logo
VCEL
Vericel
N/A
5.01
4.58

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A
Vericel Corporation stock logo
VCEL
Vericel
N/A

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
33.50%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14.36%
Vericel Corporation stock logo
VCEL
Vericel
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.38 million19.54 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.32 million168.05 millionNot Optionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14049.53 million42.42 millionOptionable
Vericel Corporation stock logo
VCEL
Vericel
30050.34 million47.73 millionOptionable

Recent News About These Companies

Vericel Corporation: Moving From Sell To Neutral

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$25.74 +1.49 (+6.14%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$26.04 +0.31 (+1.18%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$16.30 +0.37 (+2.32%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$15.90 -0.40 (-2.45%)
As of 07:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$53.46 +3.19 (+6.35%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$54.01 +0.55 (+1.03%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Vericel stock logo

Vericel NASDAQ:VCEL

$41.50 +1.33 (+3.31%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$42.12 +0.63 (+1.51%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.